Best Adenoviral Vector CDMOs in United States
· updated as new inspection, certificate, and trial data enters the platform
3
CDMOs tracked
3
Fully scored
1
With FDA records
6
FDA inspections
10
EMA/MHRA GMP certs
Adenoviral vector CDMOs make replication-deficient adenovirus for gene therapy and vaccines, using producer cell lines (e.g. HEK293), suspension bioreactors, and chromatographic purification. The platform reaches high titers, which suits vaccine-scale demand.
Selecting an adenoviral CDMO turns on serotype and producer-line experience, suspension scale, full/empty particle control, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 3 NAI (no action), 3 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (8), United States (6), Ireland (1), UNITED STATES (1).
Last updated 2026-03-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
81.0 | 100.0 | 6 insp · 10 GMP | Available | 2 programs |
| 2 |
VE
Vigene Biosciences
Rockville, MD
|
72.5 | — | — | — | 0 programs |
| 3 |
EM
Emergent BioSolutions (CGT)
Baltimore, MD
|
71.0 | — | — | — | 4 programs |
What to evaluate in a Adenoviral Vector CDMO
Producer line & serotype
Confirm experience with your serotype (Ad5 and others) and producer cell line, and whether the process is suspension-adapted for scale.
Scale & titer
Adenovirus reaches high titers for vaccine-scale demand. Match validated bioreactor scale to your dose and volume.
Particle quality
Full/empty particle ratio and aggregate control affect potency and safety. Ask about the analytics package.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
FDA jurisdiction — how the ranking scores US-based CDMOs
The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.
Which US CDMOs also cover EU and UK regulatory geographies?
Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.
How CDMO Signal identifies US manufacturing presence
Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.
Adenoviral Vector CDMOs — Frequently Asked Questions
Who are the top Adenoviral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Adenoviral Vector CDMOs include Thermo Fisher Scientific, Vigene Biosciences, Emergent BioSolutions (CGT). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Adenoviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 1 Adenoviral Vector CDMO with FDA inspection records and 10 EMA/MHRA GMP certificates across the group.
What should I look for in an adenoviral vector CDMO?
Confirm serotype and producer-line experience, a suspension process at your required scale, strong particle-quality analytics, and a clean FDA and EMA/MHRA record.
How is adenoviral vector manufacturing different from AAV?
Both are non-enveloped viral vectors made in HEK293-type lines, but adenovirus is larger and drives strong transient expression (suiting vaccines), while AAV is the workhorse for durable in vivo gene therapy.
Related modalities